HARRISBURG, Pa., May 16, 2017 /PRNewswire/ -- PinnacleHealth CardioVascular Institute enrolled the first patient
Biosensors International Group, Ltd, a developer, manufacturer and marketer of innovative medical devices, is testing its BioFreedom™ drug-coated stent in the LEADERS FREE II Pivotal Study with the therapeutic focus on patients at high bleeding risk (HBR) who can only receive an ultra-short dual anti-platelet regimen of only one month. William Bachinsky, MD, FACC, medical director of cardiac catheterization labs at PinnacleHealth CardioVascular Institute, serves locally as principal investigator at PinnacleHealth.
Coronary artery disease is the narrowing or blockage of vessels that carry blood to the heart muscle, effecting millions of Americans and results in symptoms of shortness of breath, chest pain, heart attack and death. Blockages of the heart arteries are often treated with stents, thin metallic scaffolds that are implanted to help open the artery and alleviate these issues. Most patients require two anti-platelet medications for the first few months after the procedure, which for some patients is a concern because of an increased risk for bleeding. An option to reducing the length of time needed for these extra blood thinners would be favorable for HBR patients.
"We are very excited to be the first to treat a Pennsylvania patient in the global study testing a heart stent that may require shorter dual antiplatelet medication for patients with coronary heart disease," said Dr. Bachinsky. "The polymer-free BioFreedom™ stent may allow us to address the unmet need of our patients, who are at higher risk for bleeding, but require treatment with an active stent.
The BioFreedom™ drug-coated stent (DCS) has been implanted to date in more than 150,000 patients in more than 40 countries outside the United States. The BioFreedom™ DES has CE mark approval and is commercialized outside of the US. The LEADERS FREE II trial will be conducted at up to 85 clinical sites in the United States, Canada, Denmark, France, Germany, Italy, and the United Kingdom.
About PinnacleHealth System
PinnacleHealth System has been a leading provider of inpatient and outpatient healthcare services in central Pennsylvania since 1873. The 627-bed system has three acute care hospitals (Community General Osteopathic, Harrisburg and West Shore Hospitals) on four campuses (Community, Harrisburg, Polyclinic and West Shore) serving a five-county service area and supporting rural hospitals through affiliations and telehealth services. PinnacleHealth pursues innovative treatment options for the region through cardiac and cancer clinical trials, while offering convenient community services including medical home-certified primary care, urgent care, Magnet-recognized nursing excellence, emergency services, imaging, high-volume maternity care and a level III NICU, and workplace-based wellness services. PinnacleHealth includes a CardioVascular Institute and Cancer Institute, as well as a Bone and Joint Institute, Neurosurgery and Neurosciences Institute, and Spine Care Center that combine a multi-disciplinary approach to comprehensive spine, bone, joint, orthopedic and sports medicine services. PinnacleHealth is recognized for high-quality care with national and regional recognitions for volumes, outcomes and safety. For more information, visit pinnaclehealth.org.
Press contact: Kelly McCall PinnacleHealth System 717-231-8104 (office) [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/first-pennsylvania-patient-treated-in-landmark-heart-artery-stent-trial-300456808.html
SOURCE PinnacleHealth System
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All